tert-butyl-4-(quinolin-3-yl)piperazine-1-carboxylate | 684250-01-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: tert-butyl-4-(quinolin-3-yl)piperazine-1-carboxylate
• 英文别名: tert-butyl4-(quinolin-3-yl)piperazine-1-carboxylate；4-quinolin-3-yl-piperazine-1-carboxylic acid tert-butyl ester；1,1-dimethylethyl 4-(3-quinolinyl)-1-piperazinecarboxylate；tert-butyl 4-(quinolin-3-yl)piperazine-1-carboxylate；4-Quinolin-3-yl-piperazine-1-carboxylic acid tert.-butyl ester；tert-butyl 4-quinolin-3-ylpiperazine-1-carboxylate
• CAS: 684250-01-9
• 化学式: C₁₈H₂₃N₃O₂
• mdl: MFCD11872592
• 分子量: 313.4
• InChiKey: AKMKTKSOTNQBFY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.444
• 拓扑面积：
  45.7
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl-4-(quinolin-3-yl)piperazine-1-carboxylate 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 以100%的产率得到3-(piperazin-1-yl)quinoline
  参考文献：
  名称：

  2-取代氧基-5-甲砜基苯基哌嗪酰胺类似物及 其制备方法和用途

  摘要：

  本发明公开了2‑取代氧基‑5‑甲砜基苯基哌嗪酰胺类似物及其制备方法和用途。具体地，本发明涉及一种具有式(I)化合物2‑取代氧基‑5‑甲砜基苯基哌嗪酰胺类似物及其制备方法和应用，其中式(I)化合物中的取代基如说明书所定义。该系列化合物具有抑制甘氨酸转运蛋白‑1(GlyT1)的活性，可以用来治疗中枢神经及精神领域的相关疾病，例如精神分裂症(包括阳性症状、阴性症状以及认知性症状)、老年痴呆症、帕金森氏症以及其他的相关精神类疾病，在预防与治疗中枢神经及精神疾病药物中的具有广泛应用，有望开发成新一代GlyT1抑制剂。

  公开号：

  CN105712952B
• 作为产物：
  描述：

  3-溴喹啉 、 N-Boc-哌嗪 在 SiO2 、 cyclohexane, ethyl acetate 、 cyclohexane diethyl ether 作用下， 生成 tert-butyl-4-(quinolin-3-yl)piperazine-1-carboxylate
  参考文献：
  名称：

  Phenyl-piperazine methanone derivatives, substituted by heterocyclic groups

  摘要：

  本发明涉及一般式IC的化合物，其中R2、R′、R″、R3、R6、X1和X1′如本文所定义，并且其药物活性酸盐。本发明的化合物对于治疗神经系统和神经精神疾病有用。

  公开号：

  US20070219207A1

文献信息

• Novel Aryl Piperazine Derivatives With Medical Utility
  申请人：Campiani Giuseppe

  公开号：US20090238761A1

  公开（公告）日：2009-09-24

  This invention provides novel aryl piperazine derivatives having medical utility, in particular as modulators of dopamine and serotonin receptors, preferably the D 3 , D 2 -like and 5-HT 2 receptor subtypes, and in particular useful for the treatment of neuropsychiatric disorders incl. schizophrenia.

  这项发明提供了具有医疗效用的新型芳基哌嗪衍生物，特别是作为多巴胺和5-羟色胺受体的调节剂，优选为D3、D2样和5-HT2受体亚型，特别适用于治疗包括精神分裂症在内的神经精神障碍。
• Targeting Dopamine D₃ and Serotonin 5-HT_1A and 5-HT_2A Receptors for Developing Effective Antipsychotics: Synthesis, Biological Characterization, and Behavioral Studies
  作者：Margherita Brindisi、Stefania Butini、Silvia Franceschini、Simone Brogi、Francesco Trotta、Sindu Ros、Alfredo Cagnotto、Mario Salmona、Alice Casagni、Marco Andreassi、Simona Saponara、Beatrice Gorelli、Pia Weikop、Jens D. Mikkelsen、Jorgen Scheel-Kruger、Karin Sandager-Nielsen、Ettore Novellino、Giuseppe Campiani、Sandra Gemma

  DOI：10.1021/jm501119j

  日期：2014.11.26

  Combination of dopamine D-3 antagonism, serotonin 5-HT1A partial agonism, and antagonism at 5-HT2A leads to a novel approach to potent atypical antipsychotics. Exploitation of the original structureactivity relationships resulted in the identification of safe and effective antipsychotics devoid of extrapyramidal symptoms liability, sedation, and catalepsy. The potential atypical antipsychotic 5bb was selected for further pharmacological investigation. The distribution of c-fos positive cells in the ventral striatum confirmed the atypical antipsychotic profile of 5bb in agreement with behavioral rodent studies. 5bb administered orally demonstrated a biphasic effect on the MK801-induced hyperactivity at dose levels not able to induce sedation, catalepsy, or learning impairment in passive avoidance. In microdialysis studies, 5bb increased the dopamine efflux in the medial prefrontal cortex. Thus, 5bb represents a valuable lead for the development of atypical antipsychotics endowed with a unique pharmacological profile for addressing negative symptoms and cognitive deficits in schizophrenia.
• Discovery of imidazole carboxamides as potent and selective CCK1R agonists
  作者：Cheng Zhu、Alexa R. Hansen、Thomas Bateman、Zhesheng Chen、Tom G. Holt、James A. Hubert、Bindhu V. Karanam、Susan J. Lee、Jie Pan、Su Qian、Vijay B.G. Reddy、Marc L. Reitman、Alison M. Strack、Vincent Tong、Drew T. Weingarth、Michael S. Wolff、Doug J. MacNeil、Ann E. Weber、Joseph L. Duffy、Scott D. Edmondson

  DOI：10.1016/j.bmcl.2008.06.057

  日期：2008.8

  High-throughput screening revealed diaryl pyrazole 3 as a selective albeit modest cholecystokinin 1 receptor (CCK1R) agonist. SAR studies led to the discovery and optimization of a novel class of 1,2-diaryl imidazole carboxamides. Compound 44, which was pro. led extensively, showed good in vivo mouse gallbladder emptying (mGBE) and lean mouse overnight food intake (ONFI) reduction activities. (c) 2008 Elsevier Ltd. All rights reserved.
• PHENYL-PIPERAZIN METHANONE DERIVATIVES
  申请人：F. Hoffmann-Roche AG

  公开号：EP1828154A1

  公开（公告）日：2007-09-05
• ARYL PIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS
  申请人：Universita' Degli Studi di Siena

  公开号：EP1836192A2

  公开（公告）日：2007-09-26